PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Ann Rheum Dis. 1980 October; 39(5): 457–461.
PMCID: PMC1000585

Cause of death in patients with rheumatoid arthritis with particular reference to azathioprine.

Abstract

Three hundred and eleven patients with classical or definite rheumatoid arthritis were observed over an 11-year period. This group is of particular interest since 214 patients were given cytotoxic therapy, 203 were treated with azathioprine (52 of these also received chlorambucil or cyclophosphamide), and 11 were treated with cyclophosphamide or chlorambucil alone. Forty-six patients died. This is an excess mortality compared with the expected rate for the general population matched with respect to age and sex. The death rate was higher than expected in the age group 45-64 years but lower in those aged 75 years or over. There were more deaths from neoplasia and ischaemic heart disease in the younger age group. One patient died of lymphosarcoma; treatment had been with corticosteroids, gold, and chloroquine. No other tumours of the reticuloendothelial system were recorded, and no patient developed leukaemia.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (708K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Mason M, Currey HL, Barnes CG, Dunne JF, Hazleman BL, Strickland ID. Azathioprine in rheumatoid arthritis. Br Med J. 1969 Feb 15;1(5641):420–422. [PMC free article] [PubMed]
  • Urowitz MB, Gordon DA, Smythe HA, Pruzanski W, Ogryzio MA. Azathioprine in rheumatoid arthritis. A double-blind, cross over study. Arthritis Rheum. 1973 May-Jun;16(3):411–418. [PubMed]
  • Currey HL, Harris J, Mason RM, Woodland J, Beveridge T, Roberts CJ, Vere DW, Dixon AS, Davies J, Owen-Smith B. Comparison of azathioprine, cyclophosphamide, and gold in treatment of rheumatoid arthritis. Br Med J. 1974 Sep 28;3(5934):763–766. [PMC free article] [PubMed]
  • COBB S, ANDERSON F, BAUER W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med. 1953 Oct 1;249(14):553–556. [PubMed]
  • Moesmann G. Malignancy and mortality in subacute rheumatoid arthritis in old age. Acta Rheumatol Scand. 1969;15(3):193–199. [PubMed]
  • Uddin J, Kraus AS, Kelly HG. Survivorship and death in rheumatoid arthritis. Arthritis Rheum. 1970 Mar-Apr;13(2):125–130. [PubMed]
  • Isomäki HA, Mutru O, Koota K. Death rate and causes of death in patients with rheumatoid arthritis. Scand J Rheumatol. 1975;4(4):205–208. [PubMed]
  • Mutru O, Koota K, Isomäki H. Causes of death in autopsied RA patients. Scand J Rheumatol. 1976;5(4):239–240. [PubMed]
  • Schneck SA, Penn I. De-novo brain tumours in renal-transplant recipients. Lancet. 1971 May 15;1(7707):983–986. [PubMed]
  • Penn I. The incidence of malignancies in transplant recipients. Transplant Proc. 1975 Jun;7(2):323–326. [PubMed]
  • Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med. 1973 Apr;54(4):445–452. [PubMed]
  • Cobau CD, Sheon RP, Kirsner AB. Immunosuppressive drugs and acute leukemia. Ann Intern Med. 1973 Jul;79(1):131–132. [PubMed]
  • Love RR, Sowa JM. Myelomonocytic leukaemia following cyclophosphamide therapy of rheumatoid disease. Ann Rheum Dis. 1975 Dec;34(6):534–535. [PMC free article] [PubMed]
  • Seidenfeld AM, Smythe HA, Ogryzlo MA, Urowitz MB, Dotten DA. Acute leukemia in rheumatoid arthritis treated with cytotoxic agents. J Rheumatol. 1976 Sep;3(3):295–304. [PubMed]
  • McCracken JD. Letter: Additional risk from immunosuppressive therapy for rheumatoid arthritis. Ann Intern Med. 1973 Oct;79(4):611–612. [PubMed]
  • Hunter T, Urowitz MB, Gordon DA, Smythe HA, Ogryzlo MA. Azathioprine in rheumatoid arthritis: a long-term follow-up study. Arthritis Rheum. 1975 Jan-Feb;18(1):15–20. [PubMed]
  • Tolchin SF, Winkelstein A, Rodnan GP, Pan SF, Nankin HR. Chromosome abnormalities from cyclophosphamide therapy in rheumatoid arthritis and progressive systemic sclerosis (scleroderma). Arthritis Rheum. 1974 Jul-Aug;17(4):375–382. [PubMed]
  • CAMMARATA RJ, RODNAN GP, JENSEN WN. Systemic rheumatic disease and malignant lymphoma. Arch Intern Med. 1963 Mar;111:330–337. [PubMed]
  • TALAL N, BUNIM JJ. THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME. Am J Med. 1964 Apr;36:529–540. [PubMed]
  • Miller DG. The association of immune disease and malignant lymphoma. Ann Intern Med. 1967 Mar;66(3):507–521. [PubMed]
  • Anderson LG, Talal N. The spectrum of benign to malignant lymphoproliferation in Sjögren's syndrome. Clin Exp Immunol. 1972 Feb;10(2):199–221. [PubMed]
  • Walder BK, Robertson MR, Jeremy D. Skin cancer and immunosuppression. Lancet. 1971 Dec 11;2(7737):1282–1283. [PubMed]
  • Doll R, Kinlen L. Immunosurveillance and cancer: epidemiological evidence. Br Med J. 1970 Nov 14;4(5732):420–422. [PMC free article] [PubMed]
  • Schwartz RS. Immunoregulation, oncogenic viruses, and malignant lymphomas. Lancet. 1972 Jun 10;1(7763):1266–1269. [PubMed]
  • Wall RL, Clausen KP. Carcinoma of the urinary bladder in patients receiving cyclophosphamide. N Engl J Med. 1975 Aug 7;293(6):271–273. [PubMed]
  • Dale GA, Smith RB. Transitional cell carcinoma of the bladder associated with cyclophosphamide. J Urol. 1974 Nov;112(5):603–604. [PubMed]
  • FORNI AM, KOSS LG, GELLER W. CYTOLOGICAL STUDY OF THE EFFECT OF CYCLOPHOSPHAMIDE ON THE EPITHELIUM OF THE URINARY BLADDER IN MAN. Cancer. 1964 Oct;17:1348–1355. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group